| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.06 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.06 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.07 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | 0.055 | 0.07 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.07 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.07 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.07 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.056 | 0.08 |